Life Sciences Archives - Page 5 of 17 - Becker's Hospital Review

Common drug may slow cancer spread | Drugmaker called out for false claims | Teladoc, Eli Lilly team up | 1.5M bottles of ADHD drug recalled

March 12, 2025 BHR Newsletter 1. FDA scolds drugmaker for 'false or misleading' claims Full story 2. The common drug that may prevent cancer spread Full story 3. Novo Nordisk drug yields 15.7% weight loss in phase 3 trial Full…

Malaria drug reused for cancer | FDA sued over semaglutide ruling | Eli Lilly debuts new Zepbound vials | Breast cancer drug shows promise

March 5, 2025 BHR Newsletter 1. Eli Lilly unveils high-dose, low-cost Zepbound vials Full story 2. Texas researchers repurpose malaria drug for cancer Full story 3. Growing insurer restrictions limit GLP-1 coverage: GoodRx Full story 4. Downtime costs more than…

Generic cancer drug approved | Merck jury trial delayed | Trump revisits healthcare price transparency | Vaccines for pancreatic cancer show promise

February 26, 2025 BHR Newsletter 1. Jury trial over Merck vaccine delayed Full story 2. FDA approves generic cancer treatment for 2026 availability Full story 3. Trump revisits price transparency with new executive order: 5 things to know Full story…

FDA OKs 1st rapid-acting insulin biosimilar | 4 federal healthcare updates | HHS to probe pediatric medicines | 24 drugmakers among best employers

February 19, 2025 BHR Newsletter 1. FDA OKs 1st rapid-acting insulin biosimilar Full story 2. Pfizer and Astellas drug combo doubled survival in bladder cancer patients: Study Full story 3. DOGE clears legal hurdle; Trump signs IVF order: 4 federal…

Cancer vaccine finds early success | CFOs struggle with GLP-1 costs, access | USAID trials halted | GLP-1 drug fails to slow Parkinson's

February 12, 2025 BHR Newsletter 1. Experimental cancer vaccine logs success in early trial Full story 2. 'It's a fine balance': CFOs struggle to manage GLP-1 access and costs Full story 3. Bristol Myers Squibb to reduce costs by $2B Full story…

GLP-1 approvals: A review | RFK Jr. clears 1st HHS hurdle | FDA OKs non-opioid pain med | Mounjaro could replace painful treatment

February 5, 2025 BHR Newsletter 1. FDA approves 1st-of-its-kind non-opioid pain medication Full story 2. GLP-1 drug approvals: A breakdown Full story 3. Tariffs on China threaten to drive up drug costs, exacerbate shortages: 5 notes Full story 4. The…

Moderna works on norovirus vaccines | Blood pressure treatment recalled | Ozempic OKed for kidney disease | FDA issues anaphylaxis risk warning

January 29, 2025 BHR Newsletter 1. Drugmaker recalls blood pressure treatment common in anesthesia Full story 2. Moderna races to create norovirus vaccines Full story 3. AbbVie makes deal to develop cancer, immunology treatments Full story 4. How a 900-provider…

Trump's 1st healthcare moves | AbbVie to write off $3.5B over failed drug | 3 states to sue FDA | GLP-1s linked to range of benefits

January 22, 2025 BHR Newsletter 1. AbbVie to write off $3.5B over failed schizophrenia drug Full story 2. GLP-1s linked to wide range of health benefits: Study Full story 3. President Trump's 1st-day healthcare moves: 7 things to know Full…

A new weight loss pill by 2026 | J&J buys drugmaker for $14.6B | Antidepressant fails in final stage | Top-paying healthcare jobs in 2025

January 15, 2025 BHR Newsletter 1. J&J set to acquire drugmaker for $14.6B Full story 2. New weight loss pill to be approved by early 2026: Eli Lilly Full story 3. The top-paying healthcare jobs for 2025 Full story 4.…

Google's ALS drug fails trial | Eli Lilly joins GLP-1 shortage lawsuit | Trump's impact on drug prices | 5 recent drug recalls

January 8, 2025 BHR Newsletter 1. Google's ALS drug fails phase 3 trial Full story 2. Eli Lilly to join lawsuit over GLP-1 shortage: 4 things to know Full story 3. Bone cancer drug linked to cardiovascular risk, study suggests…